ReviewFrontiers in immunology2025
Mechanisms, advances, and challenges of immunotherapy in gastric cancer.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of cytokine-induced killer cells for gastric cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- The Role of IGF2BP3-Mediated Immune Response Activation in Enhancing Immunotherapy of Koumine for Gastric Cancer.Cancer science · 2026Article
- RUNX1-Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells.Cancer science · 2026Article
- JOSD1 stabilizes SULF1 to activate Wnt7B-FZD1 signaling in gastric cancer.Translational oncology · 2026Article
- Gastric Cancer: Pathobiology and Therapeutics.MedComm · 2026Review
- Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.Frontiers in immunology · 2026Review
- A trivalent gastric cancer antigen conjugated to a diphtheria toxin epitope synergizes with an NKT cell agonist to boost antitumor immunity.Frontiers in immunology · 2026Article
- Lipid metabolism and the immune microenvironment in gastric cancer.Frontiers in immunology · 2026Review
- Editorial: Checkpoint immunotherapy: reshaping the landscape of gastrointestinal cancer treatment.Frontiers in immunology · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the most common gastrointestinal malignancies worldwide, characterized by a high incidence rate, low screening rate, and subtle early symptoms. As a result, the majority of patients are diagnosed at an advanced or metastatic stage, contributing to poor overall prognosis. In recent years, the emergence and continuous advancement of immunotherapy have revolutionized the traditional treatment landscape for GC, offering new hope for precision medicine. Immunotherapy exerts its antitumor effects primarily by modulating the immunosuppressive tumor microenvironment and includes modalities such as immune checkpoint inhibitors (ICIs), adoptive cell therapies (ACTs), and cancer vaccines. Among these, ICIs and ACT have garnered significant attention. This review summarizes the underlying mechanisms, current applications, and major challenges of immunotherapy in GC. In addition, we discuss emerging biomarkers with potential utility for predicting immunotherapeutic efficacy in GC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.